FDA Consolidates E2b Icsr Submission Toolkit With Regional Guides

Pharmacovigilance teams preparing for AEMS-ready ICSR submissions now have a consolidated reference set from FDA, covering data element specifications, XML schema files, and backwards compatibility mapping under the ICH E2B(R3) standard. The agency's guidance page, catalogued under docket FDA-2011-D-0720 and issued by the Center for Drug Evaluation and Research, brings together every technical layer required to build and validate compliant ICSR message pipelines.

The core document, the E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide, defines the data elements and message specifications governing electronic ICSR transmission for drug and biological products. Alongside it, the ICH ICSR XML Schema Set (version 2.5) and Reference Instances (version 3.1) provide the structural files needed to generate and acknowledge ICSR messages, while Example Instances (version 2.0) offer coded illustrations for implementation teams building or auditing submission workflows.

For organisations still operating on legacy E2B(R2) infrastructure, the Backwards and Forwards Compatibility materials carry direct operational weight. The BFC Mapping spreadsheet and accompanying E2B Conversion style-sheets document the field-level conversion rules between R2 and R3 message formats, giving IT and regulatory operations teams a traceable path for migration without relying on interpretation. The Appendix I (B) document formalises those rules within the ICH framework.

The FDA Regional Implementation Guide for E2B(R3) (August 2024) sits outside the core ICH specification and addresses FDA-specific requirements: regionally controlled terminology and AEMS data elements not covered by the international standard. Regulatory affairs leads managing US submissions should treat this document as the operative layer above the ICH base spec, particularly where AEMS regional fields intersect with existing safety database configurations.

Supporting information papers cover OID and UUID usage in E2B(R3) message construction, the relationship between E2B(R3) and ICH E2D(R1), and the historical context linking E2B to ICH M5 and ISO IDMP. These are reference materials rather than binding guidance, but they resolve common implementation ambiguities around identifier management and post-marketing expedited reporting alignment.

Questions on E2B(R3) implementation are directed to [email protected]; comments on the guidance may be submitted under 21 CFR 10.115(g)(5) at any time.

Teams with active ICSR submission timelines should cross-reference the August 2024 Regional Implementation Guide against current safety database configurations before the next scheduled AEMS submission cycle.

Source: FDA Center for Drug Evaluation and Research via FDA.gov guidance documents portal, 30 September 2026.